Categories AlphaGraphs, Earnings, Other Industries

New products drive sales at Abbott in Q1

Healthcare company Abbott Laboratories (ABT) reported worldwide sales of $7.4 billion for the first quarter of 2018, an increase of 16.7% versus the prior-year period, helped by new product launches.

Net earnings on a GAAP basis came in at $418 million or $0.23 per share, down slightly from the prior-year quarter. On an adjusted basis, EPS was $0.59.

Despite beating market expectations for sales and earnings, shares dipped slightly in premarket trade.

Worldwide sales in the Nutrition segment increased 7% while sales in the Diagnostics segment grew 58.7% during Q1 2018. Established Pharmaceuticals sales rose 9.9%, while Medical Devices sales improved 14.6% compared to last year.

The Medical devices segment saw good growth during the quarter, benefiting from the St. Jude Medical acquisition. Abbott’s FreeStyle Libre glucose monitoring system helped boost sales in the Diabetes Care division.

In January, Abbott received FDA approval for magnetic resonance (MR)-conditional labeling for its Quadra AssuraTM and Quadra Assura MPTM cardiac resynchronization therapy defibrillator devices and its Fortify AssuraTM implantable cardioverter defibrillator.

For full-year 2018, Abbott estimates GAAP diluted EPS from continuing operations will be in the range of $1.23 to $1.33. Adjusted diluted EPS from continuing operations is projected to range between $2.80 and $2.90.

For the second quarter of 2018, GAAP diluted EPS from continuing operations is expected to be $0.33 to $0.35. Meanwhile, the company anticipates adjusted diluted EPS from continuing operations of between $0.70 and $0.72 during this period.

Abbott Q1 2018 earnings

 

Most Popular

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

IPO News: What to look for when Elevation Oncology makes its Wall Street debut

The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have

American Airlines (AAL): Here’s what may or may not work for this airline stock

Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top